Trial Profile

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary) ; Valaciclovir (Primary)
Indications Glioma
Focus Adverse reactions; First in man; Proof of concept
Sponsors Candel Therapeutics

14 Aug 2025 According to a Candel Therapeutics media release, Additional clinical and biomarker activity data from this trial evaluating repeat doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG), is expected in Q4 2025.
01 Apr 2025 According to a Candel Therapeutics media release, the company announced the publication of a manuscript reporting the results of this trial in Neuro-Oncology, the official journal of the Society for Neuro-Oncology (22 March 2025)
14 Feb 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com